DrugBiological
TRU-015 clinical trials
Also written TRU-015.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
- TRU-015
- 3
Studies by the year they started
3 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Wyeth is now a wholly owned subsidiary of Pfizer (2) · Pfizer (1)
Studies
Open first, then newest update. How each study uses TRU-015 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study Evaluating TRU-015 in B-Cell Non-Hodgkin's LymphomaTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00521638Written as TRU-015
- Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid ArthritisTerminatedPhase 2PfizerNCT00634933Written as TRU-015
- Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus ErythematosusTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00479622Written as TRU-015
Codes
What other systems call TRU-015 · ClinicalTrials.gg INT017954
- UNII (FDA) T0N62K2M2YTRU-015One source FDA
- NCI Thesaurus C70797CD20-targeted Polypeptide TRU-015One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T0N62K2M2Y | TRU-015 | One source FDA |
| NCI Thesaurus | C70797 | CD20-targeted Polypeptide TRU-015 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.